Is baricitinib a targeted drug?

Yes, baricitinib (Baricitinib) is a targeted drug. It belongs to the drug class of Janus kinase inhibitors (JAK inhibitors). JAKInhibitors reduce inflammatory responses and abnormal activities of the immune system by inhibiting specific enzyme activities in the Januskinase (JAK) signaling pathway. In the immune system, JAK kinase plays an important signaling role in cells. When immune cells are stimulated, they will release a variety of inflammatory mediators and cytokines, such as tumor necrosis factor-α (TNF-α), interleukin- 6(IL-6) and interleukin-23 (IL-23). After binding to the receptor, these cytokines activate JAK kinase and trigger downstream signaling.